Anti-EGFR/Anti-B7-H3 CAR-T Cells
anti-egfr/anti-b7-h3 car-t cells
"A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR) and the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-EGFR/anti-B7-H3 CAR-T cells target and bind to EGFR-expressing tumor cells and B7-H3-expressing immune and tumor cells, thereby inducing selective toxicity in these cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis."